{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T23:21:45Z","timestamp":1783812105116,"version":"3.55.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Overall survival of adolescents with relapsed T-cell lymphoblastic lymphoma (T-LL) remains poor with limited options for salvage therapy. The <jats:italic toggle=\"yes\">BCL-2<\/jats:italic> inhibitor venetoclax combined with hypomethylating agents like decitabine, has shown favorable responses in elderly patients with acute myeloid leukemia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Observation:<\/jats:title>\n            <jats:p>We present the case of a 19-year-old adolescent with stage III relapsed and refractory T-LL who did not respond to 3 lines of salvage therapy. The patient was treated with venetoclax and decitabine and achieved a dramatic response.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>This case highlights the potential clinical activity of venetoclax and decitabine in relapsed T-LL.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mph.0000000000002050","type":"journal-article","created":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T16:16:41Z","timestamp":1611418601000},"page":"e991-e996","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Venetoclax and Decitabine in Pediatric Refractory T-cell Lymphoblastic Lymphoma"],"prefix":"10.1097","volume":"43","author":[{"given":"Muhammad U.","family":"Baig","sequence":"first","affiliation":[{"name":"Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rytting","sequence":"additional","affiliation":[{"name":"Pediatrics"},{"name":"Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Roth","sequence":"additional","affiliation":[{"name":"Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajaykumar C.","family":"Morani","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Nunez","sequence":"additional","affiliation":[{"name":"Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Lin","sequence":"additional","affiliation":[{"name":"Hematopathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branko","family":"Cuglievan","sequence":"additional","affiliation":[{"name":"Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,1,20]]},"reference":[{"key":"R1-20250804","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/ejh.12722","article-title":"Lymphoblastic lymphoma: an updated review on biology, diagnosis, and treatment","volume":"96","author":"Bassan","year":"2016","journal-title":"Eur J Haematol"},{"key":"R2-20250804","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"R3-20250804","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.critrevonc.2017.03.020","article-title":"Lymphoblastic lymphoma","volume":"113","author":"Cortelazzo","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"R4-20250804","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1200\/JCO.2008.19.3367","article-title":"Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group","volume":"27","author":"Burkhardt","year":"2009","journal-title":"J Clin Oncol"},{"key":"R5-20250804","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00277-006-0169-2","article-title":"Autologous peripheral blood stem cell transplantation in children with non-Hodgkin\u2019s lymphoma: a report from the Korean Society of Pediatric Hematology-Oncology","volume":"85","author":"Won","year":"2006","journal-title":"Ann Hematol"},{"key":"R6-20250804","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13045-018-0608-2","article-title":"BCL-2 as therapeutic target for hematological malignancies","volume":"11","author":"Perini","year":"2018","journal-title":"J Hematol Oncol"},{"key":"R7-20250804","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S1470-2045(20)30060-7","article-title":"Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study","volume":"21","author":"Karol","year":"2020","journal-title":"Lancet Oncol"},{"key":"R8-20250804","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov"},{"key":"R9-20250804","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol"},{"key":"R10-20250804","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"key":"R11-20250804","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrc.2015.17","article-title":"Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies","volume":"16","author":"Delbridge","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"R12-20250804","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1200\/JCO.2011.37.0981","article-title":"Targeting the B-cell lymphoma\/leukemia 2 family in cancer","volume":"30","author":"Davids","year":"2012","journal-title":"J Clin Oncol"},{"key":"R13-20250804","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1158\/2159-8290.CD-12-0208","article-title":"Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia","volume":"2","author":"Geng","year":"2012","journal-title":"Cancer Discov"},{"key":"R14-20250804","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1182\/blood-2016-09-738070","article-title":"Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia","volume":"129","author":"Frismantas","year":"2017","journal-title":"Blood"},{"key":"R15-20250804","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1158\/0008-5472.CAN-14-1849","article-title":"BH3 inhibitor sensitivity and Bcl-2 dependence in primary acute lymphoblastic leukemia cells","volume":"75","author":"Alford","year":"2015","journal-title":"Cancer Res"},{"key":"R16-20250804","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"key":"R17-20250804","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/blood-2016-03-707414","article-title":"Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia","volume":"128","author":"Khaw","year":"2016","journal-title":"Blood"},{"key":"R18-20250804","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1182\/blood-2014-05-574566","article-title":"ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia","volume":"124","author":"Peirs","year":"2014","journal-title":"Blood"},{"key":"R19-20250804","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1158\/2159-8290.CD-14-0353","article-title":"Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199","volume":"4","author":"Chonghaile","year":"2014","journal-title":"Cancer Discov"},{"key":"R20-20250804","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"key":"R21-20250804","first-page":"2115","article-title":"Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed\/refractory malignancies. Future","volume":"14","author":"Place","year":"2018","journal-title":"Oncology"},{"key":"R22-20250804","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1038\/leu.2014.44","article-title":"BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies","volume":"28","author":"Bogenberger","year":"2014","journal-title":"Leukemia"},{"key":"R23-20250804","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s00277-012-1537-8","article-title":"Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells","volume":"91","author":"Tsao","year":"2012","journal-title":"Ann Hematol"},{"key":"R24-20250804","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat Med"},{"key":"R25-20250804","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40164-019-0133-1","article-title":"Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose","volume":"8","author":"Jilg","year":"2019","journal-title":"Exp Hematol Oncol"},{"key":"R26-20250804","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"R27-20250804","first-page":"6092646","article-title":"Venetoclax in combination with decitabine for relapsed T-cell acute lymphoblastic leukemia after allogeneic hematopoietic cell transplant","volume":"2018","author":"Rahmat","year":"2018","journal-title":"Case Rep Hematol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002050","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T20:09:33Z","timestamp":1754338173000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,20]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000002050","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1,20]]},"assertion":[{"value":"2020-05-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}